Efficacy and safety of chronic antimicrobial suppression therapy for left ventricular assist device driveline infections: A single‐center descriptive experience
Radcliffe C, Doilicho N, Niu YS, Grant M. Efficacy and safety of chronic antimicrobial suppression therapy for left ventricular assist device driveline infections: A single‐center descriptive experience. Transplant Infectious Disease 2020, 22: e13379. PMID: 32574417, DOI: 10.1111/tid.13379.Peer-Reviewed Original ResearchConceptsCAS therapyDriveline infectionSuppression therapyTreatment failureVentricular assist device driveline infectionsShort-term antimicrobial therapyExperienced treatment failureTertiary transplant centerChronic kidney diseaseCornerstone of managementContinuous-flow LVADInfectious complicationsAdverse eventsLocal debridementRetrospective reviewTransplant centersKidney diseaseStable symptomsMean ageAntimicrobial therapyCommon causePatientsTherapySuccessful outcomeInfectionOver 870 days of successful antibiotic suppression therapy for VRE‐infected left ventricular assist device
Radcliffe C, Grant M. Over 870 days of successful antibiotic suppression therapy for VRE‐infected left ventricular assist device. Journal Of Cardiac Surgery 2020, 35: 1746-1748. PMID: 32557822, DOI: 10.1111/jocs.14690.Peer-Reviewed Case Reports and Technical NotesConceptsVancomycin-resistant Enterococcus faeciumSuppression therapyVentricular assist devicePocket infectionPump exchangeAssist deviceMethicillin-sensitive Staphylococcus aureusAntibiotic suppression therapyLeft ventricular assist deviceUse of daptomycinAdvanced heart failureSymptomatic adverse eventsHeartMate II LVADLong-term suppressionMultidrug-resistant pathogensSurgical drainageAdverse eventsCommon complicationHeart failureClinical challengeInfectionDevice placementTherapyEnterococcus faeciumStaphylococcus aureus